Protalix BioTherapeutics, Inc. (PBDA.F)
Frankfurt · EUR · Healthcare · Biotechnology
€2.24 (+3.94%) as of
Key statistics
- Market cap
- 180.48M
- P/E (TTM)
- 11.79
- Forward P/E
- 56.00
- EPS (TTM)
- 0.1900
- Dividend yield
- 0.00%
- 52-week range
- 1.4100 – 2.6600
- Beta
- -0.09
- Revenue (TTM)
- 80.62M
- Profit margin
- 23.50%
- Volume
- 700.00
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hackensack, NJ, United States
- Employees
- 226
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.